HCG

HCG (human chorionic gonadotropin) is a two-part glycoprotein hormone: an alpha subunit it shares with the related hormones LH, FSH, and TSH, plus a beta subunit that makes HCG unique ¹. It is the first molecule a human embryo produces, secreted by the blastocyst before implantation, and it appears in four main forms that divide the work of early pregnancy: implantation, luteal support, and blood vessel growth (angiogenesis) ¹. The beta subunit is encoded by a small gene cluster (CGB3, CGB5, CGB7, CGB8) whose protein products are nearly equivalent in function ³.

As a medicine, HCG functions as a long-acting stand-in for luteinizing hormone (LH). Its two FDA-approved uses are fertility indications: triggering final egg maturation before retrieval in assisted reproduction, and inducing sperm production in men with hypogonadotropic hypogonadism, a condition in which the pituitary produces too little gonadotropin ⁵. Community protocols also use it to maintain testicular function during testosterone therapy, and clinicians follow it in blood as a tumor marker for germ cell cancers ¹⁵. A 1970s line of research into HCG for weight loss ended in negative controlled data, and that use is now regarded as disproven ²⁶.

HCG owes its effects to a simple trick: it binds the same receptor as luteinizing hormone (LH), but it hangs around much longer. Both hormones attach to the LH/choriogonadotropin receptor (LHCGR) on cells of the testes and ovaries. LH clears in minutes, while HCG has a biphasic half-life of roughly 24 to 36 hours (practitioner consensus or product labeling), so a single dose delivers a sustained luteinizing signal. A handful of amino acids inside the receptor distinguish HCG from LH signaling ⁴.

At the receptor, HCG switches on a G protein cascade: activation of adenylyl cyclase raises cyclic AMP, which activates protein kinase A (PKA), with a parallel ERK1/2 pathway ². What happens next depends on the tissue:

• Testes: HCG drives Leydig cells to produce testosterone, the basis for inducing puberty and fertility in gonadotropin-deficient men ⁵, and the rationale for off-label use to restore suppressed testosterone after anabolic steroid use.
• Ovary: HCG triggers final egg maturation, ovulation, and formation of the corpus luteum, the gland-like structure that secretes progesterone to support early pregnancy ⁹.
• Thyroid: at high concentrations HCG cross-activates the TSH receptor, nudging thyroid hormones up and TSH down. This is why hyperemesis gravidarum severity tracks with HCG levels ²⁷. Strong thyroid autoimmunity blunts this thyroid response ²⁸.
• Placenta: HCG sustains the VEGF-MEK/ERK pathway that builds placental blood vessels; reduced HCG tracks with fewer microvessels in placental tissue ¹³. In trophoblast cell models, HCG signaling through PKA drives the cell fusion that forms the placental barrier ¹⁴.

The strongest HCG evidence comes from reproductive endocrinology, where randomized trials and meta-analyses have measured its effect directly.

• Live birth in frozen embryo transfer: a meta-analysis of 11 RCTs (9,955 women) found a modified natural cycle using an HCG trigger produced more live births than artificial-cycle preparation (41.5% vs 39.2%, roughly one extra live birth for every 23 women treated) and fewer miscarriages (13.4% vs 17.5%) ⁷. A propensity-matched comparison told a more modest story: the HCG-triggered protocol showed no statistically significant advantage over a programmed protocol without HCG (35.3% vs 28.8% live birth), suggesting HCG may be optional in some women who ovulate normally ⁸.
• Ovulation trigger equivalence: randomized data show recombinant HCG (Ovidrel) is as effective as urinary HCG (Profasi) for final egg maturation before IVF ⁹.
• Sperm production: across 50 studies of 1,583 men with hypogonadotropic hypogonadism, gonadotropin therapy induced spermatogenesis in 74% over a mean 11.8 months, and couples achieved pregnancy in 52% over a mean 19 months. Combined HCG plus FSH was clearly better than HCG alone ⁵. A classic 1992 series used 5,000 IU intramuscular twice weekly plus hMG, with spermatozoa appearing in 8 of 13 men at a mean of 19.2 months, and normal spermatogenesis achieved in 9 ⁶.
• Testosterone: HCG drives Leydig cells to raise serum testosterone, with onset within 24 to 72 hours of an injection (practitioner consensus), the effect behind HPTA restoration use and the reason it is prohibited in male sport ²².
• Veterinary: a single 1,500 IU intravenous dose induced ovulation within 48 hours in 82.4% of treated mares versus 0% of controls ¹¹. In dairy cattle, HCG pre-synchronization improved estrus expression and progesterone ¹².
• Weight loss: controlled research found no fat-loss benefit beyond the accompanying very-low-calorie diet, so this historical use is regarded as disproven ²⁶.
• Tumor marker: in testicular cancer, free beta-hCG measurement is preferred because total-hCG assays can be falsely elevated by hypogonadism itself ¹⁵. A beta-hCG above 50,000 mIU/mL was among the strongest predictors of early death during chemotherapy in a metastatic germ cell cohort ¹⁷.

Human research protocols for HCG separate into three settings: male fertility induction, the single-dose ovulation trigger in assisted reproduction, and a discontinued weight-loss protocol. The timeline above shows the step-wise male fertility regimen with the best-controlled evidence.

• Male fertility: first-line therapy combines HCG 1,000-2,000 IU two to three times weekly with FSH or hMG 75-150 IU, continued for 12 to 24 months. Mean time to sperm is 11.8 months, and dual therapy outperforms HCG alone ⁵. The classic combined regimen used 5,000 IU intramuscular twice weekly plus hMG in 13 gonadotropin-deficient men; spermatozoa appeared in 8 of 13 at a mean of 19.2 months, and normal spermatogenesis was achieved in 9 ⁶.
• ART trigger: a single urinary HCG dose of 5,000-10,000 IU, or 250 mcg recombinant HCG, is administered about 36 hours before egg retrieval once per cycle ⁹.
• Frozen embryo transfer: modified natural-cycle protocols use an r-hCG trigger to time ovulation, with the live-birth results described above ⁷.
• Luteal phase support after embryo transfer: hCG can support the luteal phase by sustaining corpus luteum progesterone output, but its prolonged LH drive raises OHSS risk, so progesterone supplementation is the standard luteal support after transfer; hCG-based luteal support remains an option in selected protocols (practitioner consensus).
• Testicular maintenance: community protocols use 250-500 IU every other day, or 1,000-1,500 IU three times weekly in 8 to 16 week blocks, for testicular support alongside testosterone therapy. This use lacks RCT evidence.
• Equine: a single 1,500 IU intravenous dose for timed ovulation ¹¹.
• Historical weight-loss protocol: 125 IU daily with severe calorie restriction for 23 to 43 days. The HCG component is unsupported by controlled evidence ²⁶.

HCG comes in two pharmaceutical forms: lyophilized (freeze-dried) urinary HCG in multi-dose vials, and recombinant HCG (250 mcg) as a ready-to-use solution or prefilled syringe that requires no mixing ⁹. Randomized data show subcutaneous and intramuscular urinary HCG produce equivalent serum levels ³⁷.

For lyophilized vials, practice is to reconstitute with bacteriostatic water (0.9% benzyl alcohol) for multi-dose use, or with the manufacturer-supplied saline or sterile water. Mix by gentle swirling, never shaking. The calculator below handles the volume math for any vial and dose.

Storage and shelf life:

• Unmixed powder: keep refrigerated at 2-8°C per labeling, with -20°C used for long-term storage in community practice.
• Reconstituted solution: keep at 2-8°C, protected from light. In-use stability is typically 28 to 60 days, with about 30 days common. Preservative-free solutions should be used within 24 hours.
• Handling: avoid repeated freeze-thaw cycles. Inspect before each use and discard if cloudy or particulate. Commercial preparations are heterogeneous glycoform mixtures, and degradation fragments accumulate over time, so degraded stock can underperform even when a qualitative test still reads positive ³³.

HCG interacts with other agents mostly through shared biology rather than drug metabolism.

• FSH and hMG: HCG plus FSH is the standard fertility combination for male hypogonadotropic hypogonadism. Combined therapy significantly outperforms HCG monotherapy for sperm induction ⁵.
• GnRH agonists and antagonists: in high-responder IVF, low-dose HCG is added to a GnRH-agonist trigger as a dual trigger, supported by systematic review and meta-analysis ⁴⁵. In frozen embryo transfer, the value of an HCG trigger remains debated because a propensity-matched analysis found similar outcomes without it ⁸.
• Testosterone and anabolic steroids: HCG is often stacked with testosterone therapy to preserve testicular volume, but HCG alone is markedly less effective at restoring spermatogenesis than combined HCG plus FSH, which is the first-line approach. Both drugs raise estradiol through aromatization ⁵.
• Aromatase inhibitors and SERMs: community protocols pair HCG with agents like anastrozole or enclomiphene to control the estradiol rise. No formal interaction studies exist.
• Methotrexate: no pharmacokinetic interaction, but beta-hCG is the marker used to judge whether methotrexate worked in ectopic pregnancy. A suboptimal day-7 decline still resolves without further intervention in 73.5% when observed to day 10 ⁴⁷.
• Thyroid hormones: HCG cross-activates the TSH receptor, so free thyroid hormones can rise in high-HCG states. Thyroid autoimmunity above certain antibody thresholds blunts this response ²⁸.
• Corticosteroids and adrenal drugs: aberrant adrenal receptors can let HCG drive cortisol excess in susceptible individuals, a rare syndrome managed with metyrapone ³¹.
• Psychotropics: in placental cell models, several common psychotropics altered cell viability at high concentrations but none changed HCG secretion at subtoxic levels ⁴⁶.

Supplement notes: oral or homeopathic HCG drops contain no biologically active intact HCG, and injectable HCG adds no fat-loss effect beyond calorie restriction ²⁶. High-dose iodine could compound transient thyroid stimulation from HCG (theoretical). Deglycosylated HCG variants in some preparations can dampen receptor signaling rather than activate it ⁴⁹.

Whether HCG produces true tolerance is an open question with mostly mechanistic evidence. Chronic high-dose exposure can blunt Leydig cell responsiveness, and HCG also suppresses the pituitary's own gonadotropin output through negative feedback while it is present ⁴². For these reasons, community protocols run HCG in discrete windows rather than continuously.

• On-cycle maintenance: 250-500 IU two to three times weekly, continuous or in 8 to 16 week blocks (community protocol).
• Post-cycle recovery: 1,000-2,000 IU every other day to three times weekly for 4 to 8 weeks after anabolic steroid use (community protocol).
• Fertility use: 1,500-5,000 IU two to three times weekly for 12 or more months. Short bursts do not work because spermatogenesis takes months, a mean of 11.8 months to first sperm in pooled data ⁵.

Fertility induction is therefore a long cycle by design: stopping early truncates sperm yield, and dual therapy with FSH matters more than cycling strategy ⁵. Signs that call for a break in community practice include estrogen-related effects (nipple sensitivity, water retention, mood changes), diminishing testicular response despite dose increases, and refractory azoospermia beyond 12 to 18 months, which argues for adding FSH rather than raising HCG further ⁶. A documented reason to stop immediately is porphyria: HCG injections triggered an acute attack in one reported case ²⁵.

HCG is rarely studied alone in fertility practice. The combinations are the headline.

• HCG + FSH/hMG: the first-line fertility pair. HCG supplies LH activity for intratesticular testosterone while FSH drives full sperm maturation; dual therapy beats HCG monotherapy across 50 studies ⁵.
• HCG + GnRH analogues: the standard dual trigger in IVF, where a GnRH-agonist trigger is reinforced with low-dose HCG, with meta-analytic support in high responders ⁴⁵.
• HCG + testosterone or anabolic steroids: HCG preserves testicular volume and Leydig cell activity while exogenous testosterone suppresses FSH. An additive estradiol burden is expected (practitioner consensus).
• HCG + aromatase inhibitors or SERMs: used in community protocols to manage the estradiol rise from HCG-driven testosterone. Not formally studied as a drug interaction.
• HCG + GLP-1 agonists: no interaction data exist, and because HCG contributes no independent fat-loss effect, co-use for weight loss is unsupported ²⁶.
• HCG + kisspeptin or gonadorelin-type analogues: redundant stimulation of the same LH axis, with no added benefit described in the research (theoretical).

HCG is an FDA-approved prescription drug, not a scheduled or controlled substance. Two pharmaceutical classes are licensed: urinary HCG (Pregnyl, Profasi, Novarel) and recombinant HCG (Ovidrel, choriogonadotropin alfa), which differ in their isoform and charge profiles ⁹. Approval covers ovulation induction and final egg maturation in assisted reproduction, and, with other gonadotropins, male hypogonadotropic hypogonadism ⁵. It is not approved for weight loss, and the FDA has required labeling stating HCG is not effective for that use. The underlying controlled evidence was negative ²⁶. Compounded HCG is available through 503A and 503B pharmacies for off-label indications such as male hypogonadism and post-cycle restoration (practitioner consensus).

Outside the US, HCG is licensed as a prescription medicine for the same fertility indications across the EU, UK, and Australia. An HCG-based immunocontraceptive vaccine advanced through phase II trials but never reached the market ²⁰.

In sport, HCG is prohibited at all times, in and out of competition, for male athletes under the WADA Prohibited List, because it stimulates natural testosterone production. It is not prohibited for female athletes. Anti-doping labs screen urine with an intact-HCG immunoassay, using a reporting threshold of 1.0 IU/L (about a 1-in-10,000 false-positive rate), and confirm with a second immunoassay or LC-MS/MS ²². Dried-blood-spot testing methods are in development to widen sample collection ³⁶.

The dominant HCG risk in women is ovarian hyperstimulation syndrome (OHSS), a response to the drug's prolonged luteinizing drive. Severe OHSS can present atypically as large pleural effusions (fluid around the lungs) with little abdominal fluid, can appear more than a week after the HCG trigger, and is managed with drainage, albumin support, and blood-clot prevention ²⁴. Multi-follicular trigger cycles also carry an inherent multiple-pregnancy risk. Prevention in high-risk ART patients hinges on trigger choice: GnRH-agonist triggers avoid the sustained hCG luteal drive and reduce OHSS risk in high responders, and low-dose hCG can be added as a dual trigger to preserve oocyte maturation while limiting risk; full-dose hCG triggers are reserved for lower-risk cycles (practitioner consensus).

For men, the main effects are the expected consequences of raising testosterone, all dose-dependent: breast tissue sensitivity or gynecomastia, water retention, acne, and mood changes. Testicular enlargement is a normal pharmacologic effect of HCG.

Other documented risks:

• Porphyria attacks: one case report describes an acute intermittent porphyria attack triggered by HCG injections. Porphyria is a contraindication ²⁵.
• Thyroid stimulation: HCG cross-activates the TSH receptor. At pregnancy-level concentrations this produces benign TSH suppression and higher free thyroid hormones ²⁷; massive HCG loads can cause overt thyrotoxicosis, as in choriocarcinoma ⁴¹.
• Rare hormonal syndromes: aberrant adrenal receptors can let HCG drive cortisol excess (pregnancy-induced Cushing syndrome) ³¹.
• Assay pitfalls: point-of-care urine tests can read falsely negative from hook-effect interference, macro-HCG immune complexes cause false-positive elevations, kidney disease slows beta-hCG clearance, and postmenopausal pituitary hCG secretion is a benign cause of elevated serum beta-hCG that can mimic pregnancy or tumor recurrence. These affect monitoring rather than drug toxicity ²³.

Contraindications from the literature include prostate cancer or other androgen-sensitive malignancies, active testicular germ cell tumors under surveillance, gestational trophoblastic disease, pregnancy beyond the single ovulatory trigger, and acute intermittent porphyria ¹⁵. High antibody levels in thyroid autoimmunity alter the thyroid response to HCG, and kidney disease confounds interpreted levels ²⁸.